Advanced search
Publication Cover
Colorectal Cancer Volume 3, 2014 - Issue 4
Submit an article Journal homepage
46
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Dilemma of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients: is Uftoral® the right answer?

Sameer Rastogi1 Department of Medical Oncology–TMC, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Bhawna Sirohi1 Department of Medical Oncology–TMC, Tata Memorial Centre, Parel, Mumbai, Maharashtra, IndiaCorrespondence[email protected]
,
Kedar Deodhar2 Department of Pathology–TMC, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Nitin Shetty3 Deaprtment of Radiology–TMC, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
&
Shailesh V Shrikhande4 Department of GI & HPB Surgery–TMC, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
Pages 315-319 | Published online: 13 Oct 2014

References

  • van Kuilenburg AB , MullerEW, HaasjesJet al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res.7(5), 1149–1153 (2001).
  • van Staveren MC , GuchelaarHJ, van KuilenburgAB, GelderblomH, MaringJG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J.13(5), 389–395 (2013).
  • Johnson MR , YanJ, ShaoL, AlbinN, DiasioRB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J. Chromatogr. B Biomed. Sci. Appl.696(2), 183–191 (1997).
  • Cubero DI , CruzFM, SantiP, SilvaID, Del GiglioA. Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther. Adv. Med. Oncol.4(4), 167–172 (2012).
  • Ashley AC , SargentDJ, AlbertsSRet al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer110(3), 670–677 (2007).
  • Gravalos C , SalutA, Garcia-GironCet al. A randomized Phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin. Transl. Oncol.14(8), 606–612 (2012).
  • Grem JL . 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investig. New Drugs18(4), 299–313 (2000).
  • Saif MW , SyrigosK, MehraR, MattisonLK, DiasioRB. Dihydropyrimidine dehydrogenase deficiency (Dpd) in GI malignancies: experience of 4-Years. Pak. J. Med. Sci.23(6), 832–839 (2007).
  • Caudle KE , ThornCF, KleinTEet al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther.94(6), 640–645 (2013).
  • Kleibl Z , FidlerovaJ, KleiblovaPet al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma56(4), 303–316 (2009).
  • Deenen MJ , TerpstraWE, CatsA, BootH, SchellensJH. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann. Int. Med.153(11), 767–768 (2010).
  • Deenen MJ , CatsA, BeijnenJH, SchellensJH. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Ther. Adv. Med. Oncol.5(1), 91–92 (2013).
  • Kim WY , NakataB, HirakawaK. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci.98(10), 1604–1608 (2007).
  • Douillard JY , HoffPM, SkillingsJRet al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20(17), 3605–3616 (2002).
  • Fischer von Weikersthal L , SchalhornA, StauchMet al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur. J. Cancer47(2), 206–214 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.